Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Are the Latest Market Insights for the Oncology Clinical Trials Industry?
The market size of clinical trials in oncology has experienced robust growth lately. It is projected to swell from $14.04 billion in 2024 to reach $14.99 billion in 2025, with a compound annual growth rate (CAGR) of 6.8%. This historical trend in growth can be ascribed to a myriad of factors such as the rising occurrence of cancer, the escalating adoption of cancer therapies targeting specific types, an increase in awareness regarding early detection and screening of cancer, a surge in the number of clinical research organizations specialized in oncology, and the boosted patient involvement via advocacy groups.
The market size for oncology clinical trials is predicted to exhibit notable expansion in the forthcoming years, reaching $19.22 billion by 2029 and displaying a compound annual growth rate (CAGR) of 6.4%. The anticipated growth within the forecast period can be associated with the escalating demand for personalized precision oncology therapeutics, enhanced emphasis on rare and orphan oncology indications, the uptrend in the acceptance of decentralized and virtual oncology trials, and the mounting use of genomic sequencing in the selection of trial patients. Key trends during this predicted period encompass advancements in biomarker-centric trials, refined data analytics in trial structuring, breakthroughs in immuno-oncology treatments, the merging of artificial intelligence and machine learning, progress in patient-focused trial models, and the incorporation of real-world data into trial assessments.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27371&type=smp
What Forces Are Driving The Growth Of The Oncology Clinical Trials Industry?
Rising cancer rates are anticipated to fuel the expansion of the oncology clinical trials market in the future. Cancer rates denote the quantity of newfound cancer incidents within a certain group over a specified time span. The rise in cancer rates is largely attributed to detrimental lifestyle practices such as poor nutrition, sedentary behavior, tobacco usage, and overconsumption of alcohol, which collectively heightens the likelihood of obtaining various cancers. Oncology clinical trials enhance cancer treatment by assessing new treatment techniques and measures, thereby improving patient prognosis via research grounded in evidence. These trials expedite medical advancements by examining safety and effectiveness, hence promoting development in cancer prevention, detection, and treatment. For example, as reported by the Australian Institute of Health and Welfare, a government agency based in Australia, in July 2024, 160,570 cancer cases were diagnosed in Australia in 2022, signifying a growth of 3,789 cases from 156,781 in 2021. Consequently, the surge in cancer rates is fuelling the expansion of the oncology clinical trials market.
What Is The Overview Of Market Segmentation In The Oncology Clinical Trials Industry?
The oncology clinical trials market covered in this report is segmented
1) By Phase: Phase I, Phase II, Phase III, Phase IV
2) By Study Design: Interventional, Observational, Expanded Access
3) By Therapeutic Modality: Immunotherapy, Targeted Therapy, Chemotherapy, Cell And Gene Therapy, Other Therapeutic Modalities
4) By Indication: Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Blood Cancer, Other Indications
5) By Sponsor Type: Pharmaceutical And Biotech Companies, Academic And Research Institutes, Government Organizations, Other Sponsor Types
Subsegments:
1) By Phase I: Safety And Dosage Studies, Pharmacokinetics And Pharmacodynamics Studies, Biomarker Identification Studies
2) By Phase II: Efficacy And Side Effects Studies, Dose-Response Relationship Studies, Therapeutic Effectiveness Studies
3) By Phase III: Large-Scale Efficacy Studies, Comparative Effectiveness Studies, Multicenter Randomized Controlled Trials
4) By Phase IV: Post Marketing Surveillance Studies, Long-Term Safety Studies, Quality Of Life Studies
What Future Market Trends Are Projected For The Oncology Clinical Trials Industry?
Key players in the oncology clinical trials market are concentrating their efforts on creating innovative solutions with technology, such as advanced bioinformatics platforms. These solutions aim to improve data analysis, speed up patient recruitment, and optimize trial results. Advanced bioinformatics platforms operate as high-end software systems that utilize computation tools and algorithms to gather, scrutinize, and interpret intricate biological and clinical data for research and healthcare uses. One example is Deep 6 AI, a healthcare tech company from the US, which in September 2023 introduced an AI-powered genomics module. This module was created to expedite enrollment in precision medicine and oncology clinical trials. The platform uses artificial intelligence and natural language processing to derive structured and unstructured genomic data from electronic medical records. This allows for the real-time recognition and accurate pairing of patients with specific genetic markers. Researchers are then able to sift through millions of records for more than 19,000 genes and 30,000 mutation names. This greatly speeds up patient recruitment and increases the efficiency of clinical trial design.
Who Are The Primary Players Operating Across The Global Oncology Clinical Trials Market?
Major companies operating in the oncology clinical trials market are Pfizer Inc., Johnson & Johnson, Merck And Co. Inc., AbbVie Inc., Bayer AG, Novartis International AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, GSK plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Genentech Inc., BeiGene Ltd., Seagen Inc.
Get The Full Report Here:
https://www.thebusinessresearchcompany.com/report/oncology-clinical-trials-global-market-report
Which Region Offers The Most Growth Potential For The Oncology Clinical Trials Market Through 2029?
North America was the largest region in the oncology clinical trials market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oncology clinical trials market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=27371&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model